Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,670,836 papers from all fields of science
Search
Sign In
Create Free Account
HRPC
Known as:
hormone refractory prostate cancer
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Prostatic Neoplasms
hormone related neoplasm/cancer
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
H. B. Breitz
,
L. Roman
,
+4 authors
D. Karlin
2008
Corpus ID: 74349309
5153 Background: Picoplatin(Pico) is a platinum therapy specifically designed to overcome platinum resistance and to improve…
Expand
2008
2008
A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC)
E. Beardsley
,
S. Ellard
,
S. Holte
,
S. North
,
E. Winquist
,
K. Chi
2008
Corpus ID: 74044870
16098 Background: Sorafenib is a multi-targeted kinase inhibitor associated with discordant PSA and clinical responses in…
Expand
2008
2008
A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367
N. Hahn
,
R. Zon
,
+7 authors
C. Sweeney
2008
Corpus ID: 79209632
16019 Background: Chemotherapy options after docetaxel based regimens for HRPC are needed. The multi-targeted anti-folate…
Expand
2008
2008
Outcome of second-line chemotherapy with a combination of docetaxel and carboplatin (DC) in docetaxel-resistant (DR) hormone refractory prostate cancer (HRPC) patients
V. Gruenwald
,
P. Ivanyi
,
+4 authors
C. Reuter
2008
Corpus ID: 78529650
16090 Background: Docetaxel is the standard chemotherapy for HRPC. However, a standard protocol has not yet been defined for…
Expand
2007
2007
Prostate Cancer Symposium 2007 : 15 abstracts with comments
K. DeJong
2007
Corpus ID: 36782193
1 = number of abstract – I’ll ask to have CRP added to my monthly bloodtest 2 – I’ll ask to have LDH added to my monthly…
Expand
2005
2005
Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial
A. A. Meluch
,
D. Spigel
,
+5 authors
J. Hainsworth
2005
Corpus ID: 74734070
4735 Background: Docetaxel (75mg/m2 every 3 weeks) is now standard first-line treatment for patients (pts) with HRPC. Bortezomib…
Expand
2004
2004
Response to second-line taxane-based therapy after first-line epothilone B analogue BMS-247550 (BMS) therapy in hormone refractory prostate cancer (HRPC)
J. Rosenberg
,
M. Galsky
,
V. Weinberg
,
W. Kelly
,
E. Small
2004
Corpus ID: 196429067
4564 Background: Epothilone analogues and taxanes exert anti-cancer activity by interfering with microtubule function. BMS is an…
Expand
2003
2003
Therapeutic Options in Hormone Refractory Prostate Cancer
A. Heidenreich
2003
Corpus ID: 67985430
Adenocarcinoma of the prostate is the most prevalent tumor in men, a major cause of morbidity and mortality mainly because of the…
Expand
2002
2002
Molecular Dynamics Simulations of Prostaglandin Endoperoxide H Synthase-1. Role of Water and the Mechanism of Compound I Formation from Hydrogen Peroxide
R. Cukier
,
S. Seibold
2002
Corpus ID: 94659019
Molecular dynamics (MD) is used to study the resting state and hydrogen peroxide-bound state of Prostaglandin endoperoxide…
Expand
Review
1997
Review
1997
Prostate Cancer SEER Incidence of Distant Disease
J. Moul
1997
Corpus ID: 11456638
The traditional definition of “metastatic” prostate cancer refers to disease stage and traditionally has included only patients…
Expand